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Patent Eligibility and Cancer Therapy
Christopher B. Seaman*
As an empirical legal scholar,1 I am pleased to report that
Sasha Hoyt has done what very few law students—and even
many law professors2—could achieve. She successfully
conducted a novel empirical study to assess the real-world
impact of a U.S. Supreme Court decision, Mayo Collaborative
Services v. Prometheus Laboratories, Inc.,3 on venture capital

* Professor of Law and Director, Frances Lewis Law Center,
Washington and Lee University School of Law. I thank Lauren Robertson and
Elizabeth Hudson for inviting me to participate in the Washington and Lee
Law Review Student Notes Colloquium, and I particularly thank Alexandra
(Sasha) Hoyt for asking me to serve as the Faculty Advisor for her Note. This
Comment is dedicated to my family, and all those who are fighting or have
fought cancer.
1. See generally Christopher B. Seaman, Noncompetes and Other
Post-Employment Restraints on Competition: Empirical Evidence from Trade
Secret Litigation, 72 HASTINGS L.J. 1183 (2021); David S. Levine & Christopher
B. Seaman, The DTSA at One: An Empirical Study of the First Year of
Litigation Under the Defend Trade Secrets Act, 53 WAKE FOREST L. REV. 105
(2018); Ryan T. Holte & Christopher B. Seaman, Patent Injunctions on Appeal:
An Empirical Study of the Federal Circuit’s Application of eBay, 92 WASH. L.
REV. 145 (2017); Christopher B. Seaman, Permanent Injunctions in Patent
Litigation After eBay: An Empirical Study, 101 IOWA L. REV. 1949 (2016);
Christopher B. Seaman, Ongoing Royalties in Patent Cases After eBay: An
Empirical Assessment and Proposed Framework, 23 TEX. INTELL. PROP. L.J.
203 (2015); Christopher B. Seaman, Willful Patent Infringement and
Enhanced Damages After In re Seagate: An Empirical Study, 97 IOWA L. REV.
417 (2012).
2. See Kathryn Zeiler, The Future of Empirical Legal Scholarship:
Where Might We Go From Here?, 66 J. LEGAL EDUC. 78, 81, 87–90 (2016)
(criticizing the quality of empirical research published in student-edited law
reviews and blaming in part law professors’ lack of training to conduct such
studies).
3. 566 U.S. 66 (2012).
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(VC) investment in startups and other companies that develop
medical diagnostic technology.4
As Ms. Hoyt notes, patent protection is particularly
important for startup companies, as it can help protect their
innovations from unauthorized use, attract funding and other
investments, and foster collaboration with third parties.5 In the
Mayo case, the Supreme Court made it extremely difficult for
medical diagnostic companies to obtain patent protection for
their technology, no matter how novel or useful it is.6 Using a
sophisticated difference-in-difference methodology to evaluate
the impact of the Supreme Court’s decision in Mayo on VC
funding for medical diagnostic startups, Ms. Hoyt finds that
medical diagnostics firms received almost $10 billion less in VC
funding that they would have compared to other industries that
were unaffected by the decision.7 And importantly, this result is
statistically significant using an ordinary least squares (OLS)

4. See generally A. Sasha Hoyt, Note, The Impact of Uncertainty
Regarding Patent Eligible Subject Matter for Investment in U.S. Medical
Diagnostic Technologies, 79 WASH. & LEE L. REV. 393 (2022) (finding that the
U.S. Supreme Court’s decision in Mayo and subsequent Federal Circuit
decisions regarding patent ineligibility of medical diagnostics has resulted in
$9.2 billion less investment in medical diagnostic technologies than otherwise
would have occurred).
5. See id. at 397.
6. See Illumina, Inc. v. Ariosa Diagnostics, Inc., 967 F.3d 1319, 1325
(Fed. Cir. 2020) (“Under Mayo, we have consistently held diagnostic claims
unpatentable as directed to ineligible subject matter.”); Athena Diagnostics
Inc. v. Mayo Collaborative Servs., LLC, 927 F.3d 1333, 1352 (Fed. Cir. 2019)
(Moore, J., dissenting from denial of rehearing en banc) (“Since Mayo, we have
held every single diagnostic claim in every case before us ineligible.”); see also
Shahrokh Falati, Patent Eligibility of Disease Diagnosis, 21 N.C. J.L. & TECH.,
March 2020, at 63, 67 (“[T]he Supreme Court’s recent Mayo decision resulted
in a dramatic increase in patent offices [sic] rejecting applications related to
personalized medicine and medical diagnostics fields.”); Shridhar Jayanthi,
Note, A Potential Eligibility Safe Harbor for Diagnostic Patents Creates More
Confusion in the Alice/Mayo Test, 34 HARV. J.L. & TECH. DIGEST 1, 1 (2021)
(“[S]ince Mayo, diagnostic claims have frequently been found to be
patent-ineligible under Section 101.”); Philip Merksamer, Ariosa Diagnostics
v. Sequenom: Metastasis of Mayo and Myriad and the Evisceration of Patent
Eligibility for Molecular Diagnostics, 31 BERKELEY TECH. L.J. 495, 517–18
(2016) (explaining that “the Federal Circuit has adopted a broad and exacting
interpretation of Mayo” which “has foreclosed patent eligibility for some
important diagnostic innovations”).
7. Hoyt, supra note 4, at 442.
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regression analysis.8 In short, Ms. Hoyt’s Note is a valuable
contribution to the literature on patent eligibility and its impact
on innovation, and policymakers should take note of her study.9
In the remainder of this Comment, I build upon Ms. Hoyt’s
contributions by discussing the importance of patent protection
as an incentive to help develop better diagnostics and
treatments for a particular category of illness: cancer. Once
considered a monolithic disease classified primarily by cancer
cells’ site of origin (e.g., breast cancer, prostate cancer), modern
genetic research has discovered that cancer is enormously
complex,10 and it is often the result of the multiple mutations
that accumulate over time.11 Moreover, tumors undergo an
evolutionary process in the human body and can develop into
genetically distinct subclones that are resistant to therapy.12 As
a result, “what we call ‘cancer’ is, in actuality, a multitude of
hundreds of separate diseases with no single etiological
source.”13
Medical diagnostics are critically important to fighting
cancer in at least four ways. First, medical diagnostics involve
the discovery and use of biomarkers that indicate the presence
8. Id.
9. Cf. Comment of A. Sasha Hoyt, In the Matter of Request for
Comments on the Current State of Patent Eligibility Jurisprudence in the
United States, Docket No. PTO-P-2021-0032, U.S. Patent & Trademark Office
(Oct. 12, 2021), https://perma.cc/6ELT-BQXS (informing the U.S. Patent and
Trademark Office of the negative correlation between patent eligibility and VC
funding for medical diagnostics found in Ms. Hoyt’s Note).
10. See SIDDHARTHA MUKHERJEE, THE EMPEROR OF ALL MALADIES: A
BIOGRAPHY OF CANCER 183 (2010) (“[C]ancer, a shape-shifting disease of
colossal diversity, [was] recast as a single, monolithic entity.”).
11. See Iñigo Martincorena & Peter J. Campbell, Somatic Mutations in
Cancer and Normal Cells, 349 SCIENCE 1483, 1483 (2015) (“[T]he progressive
accumulation of mutations throughout life can lead to cancer . . . .”); Iñigo
Martincorena et al., Universal Patterns of Selection in Cancer and Somatic
Tissues, 171 CELL 1029, 1034 (2017) (noting that there are over 250 known
cancer genes).
12. Roberto Vendramin et al., Cancer Evolution: Darwin and Beyond,
EMBO J., Aug. 30, 2021, at 18; Mel Greaves & Carlo C. Maley, Clonal Evolution
in Cancer, NATURE, Jan. 18, 2012, at 5. Cancer researcher Peter Nowell, who
was a co-discoverer of the Philadelphia chromosome (a gene translocation
present in certain kinds of leukemia), is credited with developing the theory of
Darwinian-like evolution in cancer cells. See Peter C. Nowell, The Clonal
Evolution of Tumor Cell Populations, 4260 SCIENCE 23, 23–24 (1976).
13. Jacob S. Sherkow, Cancer’s IP, 96 N.C. L. REV. 297, 305–06 (2018).
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of cancer.14 To effectively treat a patient, physicians must first
determine what medical condition or disease the patient has. A
biomarker is “a biological molecule found in blood, other body
fluids, or tissues that is a sign of a normal or abnormal process,
or of a condition or disease.”15 In other words, a biomarker
requires the discovery of a naturally-occurring relationship
between a biological process in the human body and the
presence and level of a corresponding substance produced by or
related to that process.
In oncology, medical diagnostics have led to the
development of tests that can detect the presence and levels of
biomarkers for specific types of cancer.16 For instance,
prostate-specific antigen (PSA) is a well-known biomarker for
prostate cancer, one of the most common types of cancer
affecting men.17 While PSA naturally occurs at low levels in all
adult males, an elevated level—particularly one that increases
significantly over time, in both absolute and relative terms—is
correlated with prostate cancer.18 Since the FDA’s approval of a
PSA screening test in 1994,19 thousands of prostate cancer cases
have been discovered, although current evidence is mixed about
whether the benefit of lives saved due to routine PSA screening
is outweighed by complications caused by cancer treatment, the

14. Kyle Strimbu & Jorge A. Tavel, What Are Biomarkers?, CURRENT OP.
HIV & AIDS, Nov. 2010, at 2.
15. Biomarker, NAT’L CANCER INST., https://perma.cc/MFG3-EQDQ.
16. See generally N. Lynn Henry & Daniel F. Hayes, Cancer Biomarkers,
6 J. MOL. ONCOLOGY 140 (2012).
17. See generally William J. Catalona, History of the Discovery and
Clinical Translation of Prostate-Specific Antigen, 1 ASIAN J. UROLOGY 12
(2015); Danil V. Makarov & H. Ballentine Carter, The Discovery of Prostate
Specific Antigen as a Biomarker for the Early Detection of Adenocarcinoma of
the Prostate, 176 J. UROLOGY 2385 (2006).
18. See Prostate-Specific Antigen (PSA) Test, NAT’L CANCER INST.,
https://perma.cc/L96J-G8SR (last updated Feb. 24, 2021) (“In general,
however, the higher a man’s PSA level, the more likely it is that he has
prostate cancer. Moreover, a continuous rise in a man’s PSA level over time
may also be a sign of prostate cancer.”).
19. See PSA Test Is Approved for Use in Conjunction with Digital Rectal
Examination as Aid in Prostate Cancer Detection, 272 JAMA 1160, 1160
(1994).
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slow growth of many prostate cancers, and side effects caused
by biopsies from false positive tests.20
Biomarkers also can be used by physicians “to distinguish
between
different
possibilities . . . in
[a]
differential
diagnosis.”21 For instance, if a patient is found to have a lung
nodule during a scan, a “histologic evaluation of the biopsy
specimen can determine whether the tissue is cancer, infection,
inflammation, or another benign process. If cancer is detected,
further evaluation with specific immunohistochemical markers
can be used to try to identify the tissue of origin.”22
One particularly important new development is a “liquid
biopsy,” which consists of a “test done on a sample of blood to
look for . . . pieces of DNA from tumor cells that are in the
blood.”23 Although scientists recognized the existence of cell-free
DNA (cfNDA) circulating in the bloodstream as early as 1948, it
was not used to diagnose cancer until 2013, when cfNDA testing
inadvertently discovered carcinoma in a pregnant woman who
had undergone non-invasive prenatal testing for potential

20. Compare Paul F. Pinsky et al., Extended Mortality Results for
Prostate Cancer Screening in the PLCO Trial with Median Follow-Up of 15
Years, 123 CANCER 592 (2016) (finding no reduction in prostate cancer
mortality due to periodic PSA testing), and Richard M. Martin et al., Effect of
a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer
Mortality, 319 JAMA 883 (2018) (finding that a single PSA screening
intervention detected more prostate cancer cases but had no significant impact
on prostate cancer mortality rates after a median follow-up of ten years), with
Fritz H. Schröder et al., Prostate-Cancer Mortality at 11 Years of Follow-Up,
366 NEW ENG. J. MED. 981 (2012) (finding a 21 percent reduction in risk from
death of prostate cancer due to PSA cancer screening), and Fritz H. Schröder
et al., Screening and Prostate Cancer Mortality: Results of the European
Randomised Study for Screening of Prostate Cancer (ERSPC) at 13 Years of
Follow-Up, 384 LANCET 2027 (2014) (finding that one prostate cancer death
was averted per 781 men screened at thirteen years following PSA testing).
The current prostate cancer screening guidelines by the U.S. Preventive
Services Task Force do not recommend PSA testing for men seventy years and
older and suggest that the decision to undergo PSA testing for men between
fifty-five and sixty-nine years should be an individual one after discussing the
potential risks and benefits with their physician. See Final Recommendation
Statement: Prostate Cancer: Screening, U.S. PREVENTATIVE SERVS. TASK FORCE
(May 8, 2018), https://perma.cc/X2XV-2A88.
21. Henry & Hayes, supra note 16, at 141.
22. Id.
23. Liquid Biopsy, NAT’L CANCER INST., https://perma.cc/HD4X-TBMC.
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genetic anomalies for her fetus.24 Liquid biopsies hold “great
promise for detection, prognosis, and prediction of response to
cancer treatment.”25 For instance, genetic-screening company
GRAIL received a coveted Breakthrough Device designation
from the U.S. Food and Drug Administration (FDA) in 2019 for
its multi-cancer liquid biopsy test.26 GRAIL projects that its
liquid biopsy test could prevent up to 100,000 cancer deaths
annually if it was administered to all Americans fifty and
older.27
Prior to Mayo, the discoverers of new biomarkers like PSA
could obtain patent protection for both the biomarker molecule
itself and new diagnostic tests incorporating that biomarker.28
But because biomarker-based diagnostics rely upon a “natural
phenomena” or a “law of nature”—namely, the correlation
between the biomarker molecule and the existence and/or level
of cancer—they are normally ineligible for patenting following
Mayo.29 For instance, the Federal Circuit, applying Mayo, has
held that a cfDNA diagnostic test for genetic mutations in a
fetus was patent ineligible,30 thus casting serious doubt on
whether any cfDNA-based cancer diagnostics could be patented.
This lack of patent protection can discourage innovation and
investment in identifying and validating new and more accurate
24. Irma G. Dominguez-Vigil et al., The Dawn of the Liquid Biopsy in the
Fight Against Cancer, 9 ONCOTARGET 2912, 2912 (2018) (citing C. Michael
Osborne et al., Discordant Noninvasive Prenatal Testing Results in a Patient
Subsequently Diagnosed with Metastatic Disease, 33 PRENATAL DIAGN. 609
(2013)).
25. Id.
26. See GRAIL Announces Significant Progress with Multi-Cancer Early
Detection Test Including FDA Breakthrough Device Designation, GRAIL (May
13, 2019), https://perma.cc/CXX3-3PYQ.
27. Allysia Finley, Regulatory Hurdles Block a Cancer Miracle, WALL ST.
J. (Oct. 8, 2021, 1:35 PM), https://perma.cc/MJ33-VUP8.
28. See, e.g., U.S. Patent No. 4,446,122; U.S. Patent No. 5,599,677; U.S.
Patent No. U.S. 5,672,480.
29. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
88– 92 (2012).
30. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir.
2015), reh’g en banc denied, 809 F.3d 1282 (Fed. Cir. 2015); see also CareDx,
Inc. v. Natera, Inc., No. CV 19-0567-CFC-CJB, 2021 WL 4439600, at *14 (D.
Del. Sept. 28, 2021) (holding that three U.S. patents for a method of
determining organ transplant rejection using cfDNA are patent ineligible in
the wake of Mayo).
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biomarkers, which can be a costly and time-consuming
process.31 Without the security of patent rights, VC firms and
other investors may decline to help fund the development and
approval process for new biomarkers.32
Second, diagnostics are important in cancer treatment for
risk assessment. The presence or absence of certain genetic
markers can indicate the level of risk of contracting cancer,
disease progression, and ultimate outcome. For instance, the
BRCA1 and BRCA2 germline mutations on chromosomes 17 and
13 are correlated with a greatly increased risk of breast and
ovarian cancer among women.33 The discovery of BRCA1 and
BRCA2 led to enhanced screening, medication, and in some
cases surgery, to reduce the risk of cancer occurring in women
who had these mutations. The patent eligibility of the BRCA1
and BRCA2 genes was the subject of litigation that went all the
way to the Supreme Court, which in 2013 held that naturally
occurring DNA sequences like BRCA1 and BRCA2 were not
patent eligible, but that artificially created complementary DNA
(cDNA) sequences created through human intervention could be
patented.34
Third, diagnostics are valuable in oncology for the
development of tailored therapies. For decades, standard
cytotoxic treatments like chemotherapy and radiation were
widely used to fight cancer.35 These therapies kill cancer cells,
31. See generally BOOZ ALLEN HAMILTON, COST DRIVERS IN THE
DEVELOPMENT AND VALIDATION OF BIOMARKERS USED IN DRUG DEVELOPMENT
2– 3 (2018), https://perma.cc/JJ6U-HVHD (PDF) (noting that the mean cost of
developing a new predictive biomarker is over $15 million and can take up to
three years).
32. See Bronwyn H. Hall, Is There a Role for Patents in the Financing of
New Innovative Firms? 5 (Nat’l Bureau of Econ. Rsch., Working Paper No.
24370, 2018), https://perma.cc/PP4P-GBA2 (noting the “undoubted empirical
fact that patenting and VC funding are correlated when one looks across [VC]
firms”); see also id. at tbl.A-2 (listing studies).
33. Hereditary Breast and Ovarian Cancer: BRCA1 and BRCA2, CDC,
https://perma.cc/K9HL-DLK2 (last updated Mar. 25, 2020).
34. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576
(2013); see generally JORGE CONTRERAS, THE GENOME DEFENSE: INSIDE THE
EPIC LEGAL BATTLE TO DETERMINE WHO OWNS YOUR DNA (2021).
35. See generally MUKHERJEE, supra note 10; Vincent T. DeVita, Jr. &
Steven A. Rosenberg, Two Hundred Years of Cancer Research, 366 NEW ENG.
J. MED. 2207 (2012) (detailing the history of surgery, radiation therapy, and
chemotherapy from the 19th century through the 1990s).
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but they also destroy numerous healthy (nonmalignant) cells,
causing numerous short- and long-term side effects, including
fatigue, nausea, vomiting, weight loss, risk of infection,
permanent nerve damage, organ dysfunction, and the
development of secondary malignancies.36 And in some cases,
they are (or become) ineffective, inflicting suffering on patients
without corresponding benefit.37
As previously mentioned, historically, cancers were
classified based on where in the body they originated.38 But
thanks to advances in medical diagnostics, we know now that
cancers arising in the same organ are often fundamentally
different at a genetic level. This discovery has led to a shift
toward
tailored
therapy—also
called
personalized
medicine—that targets specific mutations that occur in a
patient’s cancer cells. 39 Diagnostic tests can now reveal whether
genetically-targeted therapy would be beneficial as a
complement or adjuvant to traditional treatments like radiation
and chemotherapy,40 or potentially replace them entirely.41
36. Chemotherapy Side Effects, AM. CANCER SOC., https://perma.cc/LKK36QLU;
Radiation
Therapy
Side
Effects,
AM.
CANCER
SOC.,
https://perma.cc/EX7K-PRPP).
37. See, e.g., Holly G. Prigerson et al., Chemotherapy Use, Performance
Status, and Quality of Life at the End of Life, 1 JAMA ONCOLOGY 778, 782–83
(2015) (discussing lack of impact of palliative chemotherapy for some patients
with end-stage cancer on their quality of life); see also Alice Park, When
Chemotherapy Does More Harm than Good, TIME (July 23, 2015, 11:00 AM),
https://perma.cc/MZZ4-ZA3X.
38. See supra notes 10–13 and accompanying text.
39. Personalized Medicine, NAT’L CANCER INST., https://perma.cc/D8EN6UTP (“A form of medicine that uses information about a person’s own genes
or proteins to prevent, diagnose, or treat disease. In cancer, personalized
medicine uses specific information about a person’s tumor to help make a
diagnosis, plan treatment, find out how well treatment is working, or make a
prognosis.”).
40. See, e.g., Howard West & Jill O. Jin, Adjuvant Therapy, 1 JAMA
ONCOLOGY 698, 698 (2015) (explaining that “adjuvant therapy refers to any
treatment that is given for cancer after the main treatment, with the goal of
making the main treatment more likely to be successful”).
41. See, e.g., Gina Kolata, Cancer Without Chemotherapy: A ‘Totally
Different World’, N.Y. TIMES, D1 (Sept. 28, 2021) (describing how oncologists
are prescribing targeted therapy as the initial treatment of certain types of
breast and lung cancer); Alice Park, No More Chemo: Doctors Say It’s Not So
Far-Fetched, TIME (June 26, 2013), https://perma.cc/B7NP-DYTG (quoting
Dr. Martin Tallman, Chief of Leukemia Service at Memorial Sloan-Kettering
Cancer Center, as stating “I think we are definitely moving farther and farther
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For instance, Herceptin (trastuzumab) is a monoclonal
antibody that is a targeted therapy for certain types of cancer,
including breast and stomach cancer, that are positive for an
oncogene called HER2.42 In combination with standard-of-care
treatment, Herceptin reduced the chance of recurrence by half
and risk of dying from breast cancer by a third.43 The basis for
Herceptin was the identification by researchers at Genentech
and UCLA of a link between the HER2 oncogene and an
aggressive form of breast cancer in the 1980s.44 After
demonstrating in clinical trials that Herceptin, which is an
anti-HER2 antibody, plus chemotherapy produced durable
responses in a significant number of HER2-positive patients,45
the FDA approved Herceptin in 1998.46 Genentech and its
parent company, Roche, obtained numerous patents on both the
monoclonal antibody and various methods of manufacturing it.47
But the underlying discovery that made Herceptin possible—the
“natural phenomena” of the HER2 oncogene and its relationship
to aggressive breast cancer—likely would not be patentable
after Mayo.48
In addition, diagnostics are important to help assess how
the human body processes anti-cancer drugs. Pharmacogenetics
is the field of study on how a patient’s genetics affect her

away from chemotherapy, and more toward molecularly targeted therapy” for
certain forms of cancer).
42. See generally ROBERT BAZELL, HER-2: THE MAKING OF HERCEPTIN, A
REVOLUTIONARY TREATMENT FOR BREAST CANCER (1998).
43. Kolata, supra note 41.
44. See generally Corinne L. Williams, H. Michael Shepard, Dennis J.
Slamon, and Axel Ullrich Honored with the 2019 Lasker-DeBakey Clinical
Medical Research Award, 129 J. CLINICAL INVESTIGATION 3963 (2019).
45. See generally Jose Baselga, Phase I and II Clinical Trials of
Trastuzumab, 12 ANNALS ONCOLOGY S49 (2001).
46. See Charles L. Sawyers, Herceptin: A First Assault on Oncogenes that
Launched a Revolution, 179 CELL 8, 10 (2019).
47. See, e.g., U.S. Patent No. 5,821,337; U.S. Patent No. 6,054,297; U.S.
Patent 6,407,213; U.S. Patent No. 6,627,196; U.S. Patent No. 7,371,379.
48. For instance, U.S. Patents No. 7,846,441 and No. 7,892,549, which
claimed a method of treating patients with breast cancer that overexpresses
HER2 by using a monoclonal antibody in combination with chemotherapy
and/or other monoclonal antibodies, was recently invalidated by the Federal
Circuit, although on obviousness grounds rather than lack of patent eligibility.
Genentech, Inc v. Iancu, 809 F. App’x 781, 786–87 (Fed. Cir. 2020).
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response to specific drugs.49 For instance, a gene called TPMT
encodes the thiopurine methyltransferase enzyme, which
metabolizes
common
chemotherapy
agents
like
50
6-mercaptopurine (6MP) and thiopurine.
Patients with
mutated versions of TPMT are at high risk for severe, even fatal,
toxicity if given a normal dose of one of these drugs.51
Researchers at St. Jude Children’s Hospital discovered the
relationship between the TPMT genetic polymorphism
(mutation) and TMPT deficiency in the 1990s,52 and
subsequently obtained patent rights to both isolated DNA
sequences containing the mutated TPMT gene and a diagnostic
assay (Test) for determining whether a patient has the
TPMT-deficient gene.53 Today, however, these patent claims
would almost certainly be ineligible—the naturally-occurring
DNA sequences would be unpatentable in light of Ass’n for
Molecular Pathology v. Myriad Genetics Inc.,54 and the
diagnostic test would be precluded by Mayo.
Another revolutionary development in oncology is the rise
of immunotherapy. While the existence of antibodies as part of
the adaptive immune system was discovered over a century ago,
the first antibody-based cancer therapy, rituximab, was only
approved by the FDA to treat B-cell lymphoma in 1997.55 Today,
“[a]ntibody-based therapy . . . is now one of the most successful

49. Pharmacogenetics, NAT’L CANCER INST., https://perma.cc/NP8J-72C9;
see also Liam Drew, Pharmacogenetics: The Right Drug for You, 537 NATURE
S60 (2016).
50. Eugene Krynetski & William E. Evans, Drug Methylation in Cancer
Therapy: Lessons from the TPMT Polymorphism, 22 ONCOGENE 7403, 7403
(2003).
51. Id. (citing William E. Evans et al., Altered Mercaptopurine
Metabolism, Toxic Effects, and Dosage Requirements in a Thiopurine
Methyltransferase-Deficient Child with Acute Lymphocytic Leukemia, 119 J.
PEDIATRICS 985 (1991)).
52. Eugene Y. Krynetski & William E. Evans, Pharmacogenetics of
Cancer Therapy: Getting Personal, 63 AM. J. HUM. GENETICS 11 (1998).
53. U.S. Patent No. 5,856,095 (issued Jan. 5, 1999). St. Jude’s
subsequently granted an exclusive license to the patent rights to a joint
venture of PPD, Inc., and Axys Pharmaceuticals, Inc. PPGx Secures Exclusive
Worldwide License for TPMT Testing from St. Jude Children’s Research
Hospital, PR NEWSWIRE (Apr. 7, 2000), perma.cc/4QWN-2KDM.
54. 569 U.S. 576 (2013).
55. DeVita & Rosenberg, supra note 35, at 2212.
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and important strategies for treating [cancer] patients,”56 and
dozens of antibodies have been approved or are in various stages
of clinical trials to target specific antigens that appear on cancer
cells.57 Other forms of cancer immunotherapy include antibodies
that inhibit immune system checkpoints which would otherwise
hinder the immune system’s response in attacking cancer cells
(checkpoint inhibitors); cancer “vaccines” that present antigens
to T cells, leading to their activation against cancer cells bearing
the same antigen; and genetically engineered human T cells
(CAR-T), which act as “living drugs” that target specific proteins
on the surface of cancer cells.58 These remarkable therapies
have extended survival, and even resulted in cures, in some
patients when other treatment options have failed.59
Despite its growing importance, immunotherapy is not
immune from potential patent eligibility issues. Although some
forms of cancer immunotherapy, such as CAR-T cells and
monoclonal antibodies, are “a product of genetic engineering
[that] may support a conclusion that they are a ‘manufacture’ or
‘composition of matter’” under § 101,60 they are still based on
underlying natural phenomena—namely, the existence of
naturally-occurring antigens on the surface of cancer cells and
receptors that can bind to these antigens.61 For example, in
Bristol-Meyer Squibb Co. v. Merck & Co.,62 the defendants
argued that U.S. Patent No. 9,073,994 (the ‘994 Patent), which
56. Andrew M. Scott et al., Antibody Therapy of Cancer, 12 NATURE REVS.
278, 278 (2012).
57. Id. at 281; see also David Zahavi & Louis Weiner, Monoclonal
Antibodies in Cancer Therapy, 9 J. ANTIBODIES 34 tbl.1 (2020) (listing
FDA-approved monoclonal antibodies for cancer).
58. See generally Emilie Alard et al., Advances in Anti-Cancer
Immunotherapy: CAR-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines,
and Oncolytic Viruses, and Emerging Cellular and Molecular Targets, 12
CANCERS 286 (2020).
59. See Gina Kolata, ‘Desperation Oncology’: When Patients Are Dying,
Some Cancer Doctors Turn to Immunotherapy, N.Y. TIMES (Apr. 26, 2018),
https://perma.cc/RVA9-NGER.
60. Ellen Shamasky, The Cancer Immunotherapy Pilot Program and
Chimeric Antigen Receptor T-Cell Treatments, 2018 B.C. INTELL. PROP. & TECH.
F. 1, 26 (citing Diamond v. Chakrabarty, 447 U.S. 303 (1980)).
61. See Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330, 1333
(Fed. Cir. 2021) (further describing the relationship between receptors that
are reprogrammed on CAR-T cells and antigens on the surface of cancer cells).
62. No. 15-572, 2016 WL 1698385 (D. Del. Mar. 29, 2016).
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claimed a method of treating melanoma (a type of skin cancer)
using an anti-PD-1 monoclonal antibody, was drawn to patent
ineligible subject matter because “it merely claims the result of
a natural phenomenon”: the PD-1 pathway, which cancer cells
suppress by “producing PD-1 ligands that shut down T cells and
prevent T cells from attacking them.”63 The District Court
ultimately denied the defendants’ motion to dismiss, but in
doing so, it found that the ‘994 Patent “touches upon a natural
phenomenon by using T cells to activate the immune system”—
specifically, that it “relies on the known scientific fact that
blocking activation of the PD-1 pathway causes this effect in the
body, which enables the patient’s T cells to perform their normal
biological activity of removing cancer cells.”64 As a result, the
District Court concluded that “[t]his interaction is a natural
phenomenon” under the first step of the Mayo/Alice test for
patent ineligibility.65
Fourth, diagnostics are important in oncology to assess
treatment response and provide long-term surveillance.
Biomarkers can determine whether treatments for cancer are
effective and serve as ongoing surveillance once remission has
been achieved. For example, a biomarker called CEA
(carcinoembryonic antigen) is used to monitor the progress of
colorectal cancer,66 based on a patented discovery in the 1960s
by researchers at LaRoche.67 Similarly, biomarkers like alpha
fetoprotein (AFP) are regularly monitored in germ cell tumor

63. Defendants Merck & Co., Inc. & Merck Sharp & Dohme Corp.’s Brief
Supporting Their Motion to Dismiss, Bristol-Myers Squibb Co. v. Merck & Co.,
No. 15-572 (D. Del. Aug. 28, 2015), 2015 WL 9811960.
64. Bristol-Myers Squibb, 2016 WL 1698385, at *1 n.2.
65. Id. The District Court denied the motion to dismiss under the second
step of the Mayo/Alice test, holding that disputed factual allegations about
whether the ‘994 Patent’s claims “do significantly more than simply describe
these natural relations” precluded granting the motion under Federal Rule of
Civil Procedure 12(b)(b). Id. The case ultimately was dismissed with prejudice
prior to a final judgment on the merits. Stipulation of Dismissal of Entire
Actions with Prejudice, Bristol-Myers Squibb Co. v. Merck & Co., No. 15-572
(D. Del. Jan. 20, 2017), 2017 WL 7688123.
66. Gershon Y. Locker et al., ASCO 2006 Update of Recommendations for
the Use of Tumor Markers in Gastrointestinal Cancer, 24 J. CLINICAL
ONCOLOGY 5313 (2006).
67. U.S. Patents No. 3,663,684; No. 3,697,638; No. 3,956,258.
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patients to detect early disease recurrence.68 Again, however,
the naturally-occurring correlation between these biomarkers
and disease progression or relapse are probably unpatentable
under the Court’s current patent eligibility jurisprudence.
To be sure, patent protection for diagnostics and treatment
for cancer comes at a significant cost to both patients, insurance
companies, and the public. The BRCA1/BRCA2 test was $4,000
at the time of the Supreme Court’s decision.69 Now that patent
protection is unavailable for naturally occurring DNA after
Myriad, competitors have developed and offered their own
BRCA tests for a fraction of the cost.70 And even after patent
protection has expired on Gleevec (imatinib), a drug that is used
as a first-line treatment for Philadelphia-chromosome positive
chronic myeloid leukemia (CML) and acute lymphoblastic
leukemia (ALL), it is still incredibly expensive with a retail price
of over $100,000 per year,71 costing U.S. taxpayers over $1
billion annually.72 Treatments like CAR-T cell immunotherapy
are even more expensive.73 More needs to be done to bring down
the cost of these revolutionary new therapies, and discussion of
potential reforms to the patent system that may help lower
prices is ongoing.74 But entirely eliminating patent protection
68. Timothy D. Gilligan et al., American Society of Clinical Oncology
Clinical Practice Guidelines on Uses of Serum Tumor Markers in Adult Males
with Germ Cell Tumors, 28 J. CLINICAL ONCOLOGY 3388 (2010).
69. David B. Argus, The Outrageous Cost of a Gene Test, N.Y. TIMES (May
20, 2013), https://perma.cc/95B5-HV9B.
70. Elizabeth Lopatto, Genetic Testing for Breast Cancer Gets More
Affordable, VERGE (Apr. 21, 2015, 12:01 AM), https://perma.cc/YE5W-U2TC.
71. Roxanne Nelson, Prices Drop at Last for Transformative Cancer Drug,
MEDSCAPE (Dec. 19, 2019), https://perma.cc/FAB4-HDA2.
72. Prices for and Spending on Specialty Drugs in Medicare Part D and
Medicaid: An In-Depth Analysis 44 tbl.2 (Cong. Budget Off., Working Paper
2019-02, 2019), https://perma.cc/5MUN-DJ2S.
73. See, e.g., Reith R. Sarker et al., Cost-Effectiveness of Chimeric Antigen
Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute
Lymphoblastic Leukemia, 111 J. NAT’L CANCER INST. 719, 720 (2019) (noting
that a single dose of Kymriah (tisagenlecleucel) can cost up to $475,000).
74. See Executive Order 14036, Promoting Competition in the American
Economy, 86 Fed. Reg. 36,987, 36,988 (July 9, 2021) (“[T]oo often, patent and
other laws have been misused to inhibit or delay—for years and even
decades—competition from generic drugs and biosimilars, denying Americans
access to lower cost drugs.”); see also Letter from Janet Woodcock, M.D., Acting
Commissioner of Food and Drugs, to Andrew Hirshfeld, Performing the
Functions and Duties of the Undersecretary of Commerce for Intellectual
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for medical diagnostics, and thus decreasing incentives to help
detect, treat, and cure life-threatening diseases like cancer, does
not seem to be the optimal approach.

Property and Director of the U.S. Patent and Trademark Office (Sept. 10,
2021), https://perma.cc/KD7V-JEA6 (PDF) (raising concerns regarding the
high cost of pharmaceuticals and biosimilars and raising potential reforms at
the U.S. Patent and Trademark Office to address these issues).

